Results 121 to 130 of about 39,514 (227)

THE ROLE OF PAROXETINE IN POSTMENOPAUSAL HOT-FLASHES FREQUENCY REDUCTION

Pakistan Journal of Medicine and Dentistry, 2019
Background: To evaluate the effects and safety profile of Paroxetine on hot - flashes in post - menopausal women. Methods: It was prospective open label control clinical trial.
Zareen Naz, Moosa Khan, Faiz Ahmed Siddiqui, Faiza Siddiqui   +3 more
doaj  

Sleep Bruxism: A Narrative Review of Current Concepts, Mechanisms, and Clinical Implications

Journal of the Royal Society of New Zealand, Volume 56, Issue 2, April 2026.
Sleep bruxism is defined as “masticatory muscle activity during sleep that is characterized as rhythmic (phasic) or non‐rhythmic (tonic) and is not a movement disorder or a sleep disorder.” This comprehensive narrative review synthesizes current knowledge on the prevalence, risk factors, assessment, and management of sleep bruxism.
Ramesh Balasubramaniam, Daniele Manfredini, Guangzhao Guan   +2 more
wiley   +1 more source

Effect of Cumulative Exposure on the Efficacy of Paroxetine: A Population Pharmacokinetic‐Pharmacodynamic and Machine Learning Analyses

CPT: Pharmacometrics & Systems Pharmacology
Selective serotonin reuptake inhibitors (SSRIs) are widely used in depression treatment. However, the relationship between treatment efficacy and plasma concentrations remains unclear.
Keiichi Shigetome, Tomoko Egashira, Tetsu Tomita, Nagisa Higa, Kazuma Iwashita, Kazuya Morita, Miki Nishimura, Tetsuya Kaneko, Hitoshi Maeda, Kazunori D. Yamada, Ayami Kajiwara‐Morita, Kentaro Oniki, Norio Yasui‐Furukori, Junji Saruwatari   +13 more
doaj   +1 more source

Affect, Interpersonal Behaviour and Interpersonal Perception During Open-Label, Uncontrolled Paroxetine Treatment of People with Social Anxiety Disorder: A Pilot Study [PDF]

, 2018
Background: Laboratory-based research with community samples has suggested changes in affective, behavioural and cognitive processes as possible explanations for the effects of serotonergic medications.
Bleau, Pierre, Hedeker, Donald, Moskowitz, Debbie S., Pinard, Gilbert, Rappaport, Lance M., Russell, Jennifer J.   +5 more
core   +1 more source

Patients' Perspectives on Antidepressant Discontinuation and the Pharmacists' Role

Basic &Clinical Pharmacology &Toxicology, Volume 138, Issue 4, April 2026.
ABSTRACT Antidepressant (AD) discontinuation care asks for tailored support and alignment with patients' expectations, needs and wishes. However, studies on patients' experiences and perspectives regarding the contribution of the pharmacist to AD discontinuation care are limited.
Samah Bouarfa, Wilma Göttgens, Suzanne A. Ligthart, Otto R. Maarsingh, Marcel J. Kooij, Pierre M. Bet, Jacqueline G. Hugtenburg   +6 more
wiley   +1 more source

Adding metoclopramide to paroxetine induced extrapyramidal symptoms and hyperprolactinemia in a depressed woman: a case report

Neuropsychiatric Disease and Treatment, 2016
Ryohei Igata, Hikaru Hori, Kiyokazu Atake, Asuka Katsuki, Jun Nakamura Department of Psychiatry, University of Occupational and Environmental Health, Kitakyushu, Japan Abstract: A 54-year-old Japanese woman was diagnosed with major depressive disorder ...
Igata R, Hori H, Atake K, Katsuki A, Nakamura J   +4 more
doaj  

3,4‐Methylenedioxymethamphetamine (MDMA) does not induce robust psychomotor activation and 50‐kHz ultrasonic vocalisations in tryptophan hydroxylase 2 (Tph2)‐deficient rats lacking serotonin in the central nervous system

British Journal of Pharmacology, Volume 183, Issue 7, Page 1539-1556, April 2026.
Background and Purpose 3,4‐Methylenedioxymethamphetamine (MDMA), commonly known as ecstasy, is a psychostimulant with entactogenic properties and known to induce arousal and euphoria. As an amphetamine derivate, MDMA acts on the monoamine systems in the brain and stimulates release of dopamine (DA), noradrenaline (NA) and serotonin (5‐HT), yet their ...
Tianhua Wang, Rainer K. W. Schwarting, Markus Wöhr   +2 more
wiley   +1 more source

Reasons for patient reluctance to take preventive medications for migraine: Results of the OVERCOME (US) study

Headache: The Journal of Head and Face Pain, Volume 66, Issue 4, Page 846-858, April 2026.
Abstract Objectives/Background This study was undertaken to evaluate patient reasons for nonadoption of migraine‐preventive medications. Despite clear recommendations and eligibility criteria for migraine‐preventive treatment by the American Headache Society and the availability of these treatments, many people with migraine are not taking appropriate ...
Jessica Ailani, Rose Okonkwo, Elizabeth Johnston, Helen Hochstetler, Betzaida Martinez, Anthony Zagar, Robert A. Nicholson, Bert B. Vargas, E. Jolanda Muenzel, Richard B. Lipton   +9 more
wiley   +1 more source

Pathogenesis and Therapeutics for Chronic Pruritus of Unknown Origin: A Systematic Review

International Journal of Dermatology, Volume 65, Issue 4, Page 706-723, April 2026.
ABSTRACT Chronic pruritus of unknown origin (CPUO) is a distressing condition characterized by persistent itch lasting over 6 weeks without an identifiable cause. The underlying mechanisms remain poorly understood, complicating diagnosis and treatment.
Yagiz Matthew Akiska, Isha Gandhi, Robert Adler, Deena Fayyad, Perya Bhagchandani, Shabnam Afzal, Waleed Adawi, Shivani Patel, Shawn G. Kwatra   +8 more
wiley   +1 more source

The role of peripheral serotonin in SARS‐CoV‐2 infectivity, COVID‐19 treatment and long COVID

Immunology &Cell Biology, Volume 104, Issue 4, Page 368-376, April 2026.
In this article, we discuss how SARS‐CoV‐2 infects the gastrointestinal tract, that enterochromaffin cells, the source of circulating serotonin, uniquely express viral entry receptors. We examine how this infection disrupts gut‐derived serotonin, contributing to gastrointestinal symptoms and disease severity, and link elevated plasma serotonin to COVID‐
Daniel W Thorpe, Lauren A Jones, Alyce M Martin, Rosemary A Coleman, Caitlin Allman, Rochelle A Peterson, Damien J Keating   +6 more
wiley   +1 more source